{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:38:13Z","timestamp":1779230293377,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.dsx.2012.08.003","type":"journal-article","created":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T22:01:59Z","timestamp":1350424919000},"page":"224-228","source":"Crossref","is-referenced-by-count":6,"title":["A new class of drug for the management of type 2 diabetes: Sodium glucose co-transporter inhibitors: \u2018Glucuretics\u2019"],"prefix":"10.1016","volume":"6","author":[{"given":"H.W. Esther","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ashan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jayasekera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujoy","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2012.08.003_bib0005","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2012.08.003_bib0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/dc08-9017","article-title":"Economic costs of diabetes in the U.S. in 2007","volume":"31","author":"American Diabetes Association","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2012.08.003_bib0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2012.08.003_bib0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMp068294","article-title":"Finding new treatments for diabetes-how many, how fast, how good?","volume":"356","author":"Nathan","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dsx.2012.08.003_bib0025","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jada.2008.01.047","article-title":"Management of type 2 diabets: oral agents, insulin, and injectables","volume":"108","author":"Fonseca","year":"2008","journal-title":"Journal of the American Dietetic Association"},{"key":"10.1016\/j.dsx.2012.08.003_bib0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3810\/pgm.2009.09.2056","article-title":"The impact of weight gain on motivation, compliance, and metabolic control in patients with type diabetes","volume":"121","author":"Pi-Sunyer","year":"2009","journal-title":"Postgraduate Medical Journal"},{"key":"10.1016\/j.dsx.2012.08.003_bib0035","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance in type 2 diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.dsx.2012.08.003_bib0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1463-1326.2008.00982.x","article-title":"Sodium-glucose co-transporter inhibitors: an emerging new class of oral anti-diabetic drug","volume":"11","author":"Idris","year":"2009","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.dsx.2012.08.003_bib0045","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney International"},{"key":"10.1016\/j.dsx.2012.08.003_bib0050","series-title":"Textbook of diabetes","article-title":"Metabolic disturbances in diabetes","author":"Vella","year":"2010"},{"key":"10.1016\/j.dsx.2012.08.003_bib0055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.dsx.2012.08.003_bib0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1152\/ajplegacy.1938.124.2.279","article-title":"The relationship of kidney function to the glucose utilization of the extra-abdominal tissues","volume":"124","author":"Bergman","year":"1938","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.dsx.2012.08.003_bib0065","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfq249","article-title":"Sodium-glucose transporter-2 inhibition as an antidiabetic therapy","volume":"25","author":"Ferrannini","year":"2010","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1016\/j.dsx.2012.08.003_bib0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1079\/BJN2002763","article-title":"Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins","volume":"89","author":"Wood","year":"2003","journal-title":"British Journal of Nutrition"},{"key":"10.1016\/j.dsx.2012.08.003_bib0075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.dsx.2012.08.003_bib0080","doi-asserted-by":"crossref","first-page":"32678","DOI":"10.1074\/jbc.271.51.32678","article-title":"Biophysical characteristics of the pig kidney Na+\/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2","volume":"20","author":"Mackenzie","year":"1996","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.dsx.2012.08.003_bib0085","first-page":"F10","article-title":"Renal NA+-glucose cotransporters","volume":"280","author":"Wright","year":"2001","journal-title":"American Journal of Physiology"},{"key":"10.1016\/j.dsx.2012.08.003_bib0090","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of NA+\/glucose cotransporter 1 (SGLT1)","volume":"90","author":"Zhou","year":"2003","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.dsx.2012.08.003_bib0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/diaclin.28.1.5","article-title":"Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition","volume":"28","author":"White","year":"2010","journal-title":"Clinical Diabetes"},{"key":"10.1016\/j.dsx.2012.08.003_bib0100","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1016\/S0021-9258(17)32677-7","article-title":"The high affinity Na\/glucose cotransporter. Re-evaluation and distribution of expression","author":"Lee","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.dsx.2012.08.003_bib0105","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.dsx.2012.08.003_bib0110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/diacare.13.6.610","article-title":"Glucose toxicity","volume":"13","author":"Rossetti","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2012.08.003_bib0115","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmet.2010.04.009","article-title":"The stunned \u03b2-cell: a brief history","volume":"11","author":"Ferrannini","year":"2010","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.dsx.2012.08.003_bib0120","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0026-0495(90)90120-2","article-title":"Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment","volume":"39","author":"Blondel","year":"1990","journal-title":"Metabolism: Clinical and Experimental"},{"key":"10.1016\/j.dsx.2012.08.003_bib0125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0005-2728(83)90177-9","article-title":"Phloretin \u2013 an uncoupler and an inhibitor of mitochondrial oxidative phosphorylation","volume":"722","author":"De Jonge","year":"1983","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.dsx.2012.08.003_bib0130","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/01.STR.14.3.388","article-title":"Rapid, transient drop in brain glucose after intravenous phloretin or 3-0-methyl-d-glucose","volume":"14","author":"Oldendorf","year":"1983","journal-title":"Stroke"},{"key":"10.1016\/j.dsx.2012.08.003_bib0135","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/0148607104028005364","article-title":"The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function","volume":"28","author":"Scheepers","year":"2004","journal-title":"Journal of Parenteral and Enteral Nutrition"},{"key":"10.1016\/j.dsx.2012.08.003_bib0140","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/brain\/awp336","article-title":"Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder","volume":"133","author":"Leen","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.dsx.2012.08.003_bib0145","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1248\/cpb.44.1174","article-title":"Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4\u2032-dehydroxyphlorizin derivatives based on a new concept","volume":"44","author":"Tsujihara","year":"1996","journal-title":"Chemical and Pharmaceutical Bulletin"},{"key":"10.1016\/j.dsx.2012.08.003_bib0150","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1248\/cpb.46.1545","article-title":"Na(+)-glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4\u2032-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety","volume":"46","author":"Hongu","year":"1998","journal-title":"Chemical and Pharmaceutical Bulletin"},{"key":"10.1016\/j.dsx.2012.08.003_bib0155","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-2999(00)00016-9","article-title":"Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats","volume":"391","author":"Oku","year":"2000","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.dsx.2012.08.003_bib0160","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.bjp.0703829","article-title":"Improved diabetic syndrome in C57BL\/KsJ-db\/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095","volume":"132","author":"Arakawa","year":"2001","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.dsx.2012.08.003_bib0165","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/j.lfs.2004.09.038","article-title":"Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats","volume":"79","author":"Ueta","year":"2005","journal-title":"Life Sciences"},{"key":"10.1016\/j.dsx.2012.08.003_bib0170","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.106.110296","article-title":"Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level","volume":"320","author":"Katsuno","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.dsx.2012.08.003_bib0175","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejphar.2009.07.001","article-title":"Longterm treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice","volume":"15","author":"Katsuno","year":"2009","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.dsx.2012.08.003_bib0180","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.108.140210","article-title":"Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models","volume":"237","author":"Fujimori","year":"2008","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.dsx.2012.08.003_bib0185","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2012.08.003_bib0190","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1463-1326.2010.01291.x","article-title":"The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats","volume":"12","author":"Macdonald","year":"2010","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.dsx.2012.08.003_bib0195","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.dsx.2012.08.003_bib0200","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.109.029165","article-title":"In vitro characterisation and pharmokinetics of dapagliflozin (BMS-512148), a potent sodium glucose cotransporter type 11 inhibitor, in animals and humans","volume":"38","author":"Obermeister","year":"2010","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"key":"10.1016\/j.dsx.2012.08.003_bib0205","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","article-title":"Molecular analysis of the SGLT2 gene in patients with renal glucosuria","volume":"14","author":"Santer","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.dsx.2012.08.003_bib0210","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1093\/ndt\/gfn386","article-title":"Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and futher evidence of volume depletion","volume":"23","author":"Calado","year":"2008","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1016\/j.dsx.2012.08.003_bib0215","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1177\/0091270009351879","article-title":"Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus","volume":"50","author":"Hussey","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.dsx.2012.08.003_bib0220","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/0091270009352185","article-title":"Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study","volume":"50","author":"Hussey","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.dsx.2012.08.003_bib0225","first-page":"441","article-title":"Urinary excretion of beta-thromboglobulin and N-acetyl-beta-d-glucosaminidase in type 1 diabetes: potential indicators of ealy nephropathy?","volume":"16","author":"Patrick","year":"1990","journal-title":"Diabetes and Metabolism"},{"key":"10.1016\/j.dsx.2012.08.003_bib0240","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2012.08.003_bib0245","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2012.08.003_bib0250","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2012.08.003_bib0255","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1463-1326.2010.01216.x","article-title":"Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight","volume":"12","author":"Zhang","year":"2010","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.dsx.2012.08.003_bib0265","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/0091270011400604","article-title":"SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes melltus","volume":"52","author":"Ghosh","year":"2012","journal-title":"Journal of Clinical Pharmacology"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402112001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402112001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T08:53:05Z","timestamp":1643532785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402112001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1871402112001063"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2012.08.003","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}